Abstracts tagged "Eye Disorders"

Abstract Number: 0383 • ACR Convergence 2024
Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State
Ilaria Maccora¹, hermine brunner², Mekibib Altaye³, Alexandra Duell³, Wendy Haffey⁴, Megan Quinlan-Waters³, Alyssa Sproles⁵, Sherry Thornton⁵, Virginia Miraldi Utz³, Kenneth Greis⁴ and sheila Angeles-Han⁶, ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Rula A. Hajj-Ali¹, Duvuru Geetha², Raashid Luqmani³, Christian Pagnoux⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins University, Baltimore, MD, ³University of Oxford, Abingdon, United Kingdom, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
Abstract Number: 0385 • ACR Convergence 2024
Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis
sheila Angeles-Han¹, Jordi Anton², Amra Adrovic³, Patricia Costa Reis⁴, Joke De Boer⁵, Séverine Guillaume-Czitrom⁶, Theresa Hennard⁷, Marija Jelusic⁸, Ozgur Kasapcopur⁹, Ilaria Maccora¹⁰, Hana Malcova¹¹, Joseph McDonald¹², Najima Mwase¹³, Gabriele Simonini¹⁴, Waheba Slamang¹⁵, Derrik du Toit¹⁶, Hendrike van Vollenhoven¹⁶ and Ivan Foeldvari¹⁷, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ³Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Hospital de Santa Maria, Lisbon, Portugal, ⁵Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospital of Bicetre, Kremlin-Bicêtre, France, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ¹⁰?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ¹¹FN Motol, Praha, Czech Republic, ¹²University of Chicago, Chicago, IL, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁵University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, ¹⁶Red Cross Children’s Hospital, Cape Town, South Africa, ¹⁷Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…
Abstract Number: 2502 • ACR Convergence 2024
Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
Eduardo Martin Nares, Gabriela Hernández-Molina, Diana Aguilar-León, Norma Ofelia Uribe-Uribe and Janette Furuzawa-Carballeda, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by tissue infiltration with IgG4+ plasma cells. Fibrosis in the target organs is one of…
Abstract Number: 0396 • ACR Convergence 2024
Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood
Maryrose Hahn¹, Madison Mangin², Kellen Winden³, Pui Lee⁴, Mindy Lo², Bharti Nihalani-Gangwani², Yasmin Massoudi⁵, Tate Valerio⁵, Amanda Colombo⁵, Jessica Scott⁶, Stephen Anesi⁶, C. Stephen Foster⁶, Peter Nigrovic⁷, sheila Angeles-Han⁸, Peter Chang⁶ and Margaret Chang², ¹Boston Children's Hospital, Georgetown, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Newton, MA, ⁵Massachusetts Eye Research and Surgery Institution, Waltham, MA, ⁶Massachusetts Eye Research and Surgery Institution, Waltham, ⁷Boston Children's Hospital, Brookline, MA, ⁸Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 2574 • ACR Convergence 2024
Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Mariia Pavlenko¹, Ilaria Maccora², Mekibib Altaye³, hermine brunner⁴, Alexandra Duell³, Megan Quinlan-Waters³, Alyssa Sproles¹, Sherry Thornton⁵, Virginia Miraldi Utz³ and sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …
Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli², Bilge Batu Oto¹, Vedat Hamuryudan³, Sinem Nihal Esatoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
Abstract Number: 1559 • ACR Convergence 2023
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Nuria Barroso-Garcia¹, Jose Luis Martin-Varillas², Lara Sanchez-Bilbao³, Ivan Ferraz Amaro⁴, Vanesa Calvo Río⁵, Alfredo Adán⁶, Inés Hernanz-Rodriguez⁷, Emma Beltran-Catalan⁸, David Diaz-Valle⁹, Marisa Hernandez-Garfella¹⁰, Lucia Martinez-Costa¹¹, Manuel Diaz-Llopis¹², Jose M Herreras¹³, Olga Maiz-Alonso¹⁴, Ignacio Torre-Salaberri¹⁵, Antonio Atanes Sandoval¹⁶, Santos Insua-Vilariño¹⁷, Raquel Almodovar¹⁸, Patricia Fanlo-Mateo¹⁹, Juan Ramon De Dios²⁰, Angel Garcia-Aparicio²¹, Sergio rodriguez-Montero²², Vega Jovani²³, Patricia Moya²⁴, Eva Peña Sainz-Pardo²⁵, Jose Luis Hernandez²⁶ and Ricardo Blanco²⁷, ¹Hospital Universitario Puerta del Mar, Cadiz, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Valdecilla Hospital, Santander, Spain, ⁶Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁸HOSPITAL DEL MAR, Barcelona, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, ¹¹Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹²Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹⁴University Hospital Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ¹⁷Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, ¹⁸Alcorcón Foundation University Hospital, Madrid, Spain, ¹⁹Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁰Osakidetza, Vitoria, Spain, ²¹Hospital Universitario de Toledo, Toledo, Spain, ²²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ²⁴Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ²⁵Pediatric, Hospital 12 de Octubre, Madrid, Spain, ²⁶Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
Abstract Number: 0136 • ACR Convergence 2023
The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use
Sophie Do, Jennifer Du, Jaejin An, Jim Wang and Antony Lin, Kaiser SCAL, Fontana, CA
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used for the treatment of various autoimmune diseases. The medication is generally well-tolerated. However, long-term use after 5 years may…
Abstract Number: 1915 • ACR Convergence 2023
Scleritis and Development of Autoimmune Disease: A Case Series
Tessalyn Morrison¹, Moriah Gottman², Marcia Friedman³ and Daniela Ghetie⁴, ¹University of Vermont, Burlington, VT, ²Oregon Health & Science University, Milwaukie, OR, ³Alpine Immune Sciences, Inc., Beaverton, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
Abstract Number: 0159 • ACR Convergence 2023
Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Krati Chauhan¹, Steven Scaife² and Michael Buhnerkempe¹, ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Southen Illinois University - School of Medicine., Springfield, IL
Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
Abstract Number: 2042 • ACR Convergence 2023
Intraocular Cytokine Profiling of Autoimmune Uveitis
Maryrose Hahn¹, Madison Mangin², Marc Todd¹, Pui Lee¹, Mindy Lo¹, Bharti Gangwani³, Ankoor Shah³, Amanda Colombo⁴, Jessica Scott⁴, Stephen Anesi⁴, C. Stephen Foster⁴, Peter Chang⁴, Peter Nigrovic² and Margaret Chang², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Department of Ophthalmology, Boston Children's Hospital, Boston, MA, ⁴Massachusetts Eye Research and Surgery Institution, Waltham, MA
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 0263 • ACR Convergence 2023
Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease
Taylor Koenig¹, David Fell¹, Danny Mammo¹, Chao Zhang², Sunil Srivastava¹, Careen Lowder¹, Sumit Sharma¹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic…
Abstract Number: 2045 • ACR Convergence 2023
Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Ilaria Maccora¹, Arjun Sood², Grant Schulert³, Alexandra Duell³, Preston Land⁴, Cameron C Sapp², Jennifer Huggins³, Tiffany Nguyen², Megan Quilan-Waters³, Sumit Sharma⁵, Sunil Srivastava² and Sheila Angeles-Han⁶, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Medical Center, Cincinnati, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric uveitis often requires systemic immunomodulatory therapy (IMT) to prevent sight-threatening complications. Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare autoimmune condition caused…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].